Eflornithine HCl 13.9% cream (Vaniqa) is the first topical prescription treatment to be approved for the reduction of unwanted facial hair in women. It irreversibly inhibits ornithine decarboxylase, an enzyme that catalyzes the ratelimiting step for follicular polyamine synthesis, which is necessary for hair growth.
Hirsutism can cause embarrassment and lead to anxiety and depression. There are a limited number of treatments available that vary in efficacy, degree of discomfort and cost. It is very important to make sure that the patient is aware of all the available treatment modalities, since no one method is effective for all patients or body locations, and results from therapy may not always be satisfactory.